Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Volume 342, Issue 1, Pages (January 2014)
Advertisements

Volume 2, Issue 8, Pages (August 2015)
Cell Physiol Biochem 2013;32: DOI: /
Cell Physiol Biochem 2016;38: DOI: /
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Molecular Therapy - Nucleic Acids
MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 Cell.
Cell Physiol Biochem 2017;44:1867– DOI: /
Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.
Volume 145, Issue 2, Pages (August 2013)
WT1 Promotes Invasion of NSCLC via Suppression of CDH1
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer  Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT  Zhen-Yu He, San-Gang Wu, Fang Peng,
IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling  Yuan-Hua Xu, Zheng-Li Li,
Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Hydrogen Sulfide Demonstrates Promising Antitumor Efficacy in Gastric Carcinoma by Targeting MGAT5  Rui Wang, Qilin Fan, Junjie Zhang, Xunan Zhang, Yuqi.
Volume 146, Issue 7, Pages e5 (June 2014)
Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth  Lars Henning Schmidt,
Volume 25, Issue 8, Pages (August 2017)
Volume 6, Issue 1, Pages (January 2014)
Volume 5, Issue 6, Pages (December 2013)
Uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non- Small-Cell Lung Cancer  Jun Zhou, Chenghai Wang, Weijuan Gong, Yandan.
Volume 28, Issue 2, Pages (August 2015)
Volume 152, Issue 1, Pages (January 2019)
Molecular Therapy - Nucleic Acids
Volume 145, Issue 2, Pages (August 2013)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 3, Pages (March 2017)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
Volume 142, Issue 7, Pages e2 (June 2012)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk  Xinyu Yang, Dianke Yu, Yanli Ren, Jinyu Wei, Wenting.
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 23, Issue 1, Pages (January 2015)
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Volume 6, Issue 1, Pages (January 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Lu Zheng, Nan You, Xiaobing Huang, Huiying Gu, Ke Wu, Na Mi, Jing Li 
Molecular Therapy - Nucleic Acids
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
Figure 1. RSPO3 expression is upregulated in bladder cancer
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 4, Pages (April 2017)
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma
Molecular Therapy - Nucleic Acids
LncRNA TRERNA1 Function as an Enhancer of SNAI1 Promotes Gastric Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition  Huazhang Wu, Ying.
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 18, Issue 3, Pages (March 2010)
MiR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1  Qi Song, Quanbo Ji, Jingbo Xiao, Fang Li, Lingxiong Wang, Yin.
The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2  Cheng-Cao Sun, Ling Zhang, Guang.
Molecular Therapy - Nucleic Acids
Volume 23, Issue 4, Pages (April 2015)
Volume 25, Issue 8, Pages (August 2017)
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Molecular Therapy - Nucleic Acids
Volume 24, Issue 10, Pages (October 2016)
Volume 26, Issue 9, Pages (September 2018)
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Nucleic Acids
Presentation transcript:

Molecular Therapy - Nucleic Acids Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non–small-cell Lung Cancer by Binding to EZH2 and Suppressing p57  Cheng-Cao Sun, Shu-Jun Li, Guang Li, Rui-Xi Hua, Xu-Hong Zhou, De-Jia Li  Molecular Therapy - Nucleic Acids  Volume 5, (January 2016) DOI: 10.1038/mtna.2016.94 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 LINC00511 is upregulated in primary human NSCLC and NSCLC cell lines, and benefits for prognosis. (a,b) LINC00511 is significantly decreased in primary human NSCLC tissues in comparison to adjacent-normal NSCLC tissues. n = 124 for each group. (c) The expression level of LINC00511 in ten NSCLC cell lines and normal 16HBE cells. Assays were performed in triplicate. (d) Kaplan-Meier survival analysis revealed that high-expressed LINC00511 is associated with poor prognosis in patients with non–small-cell lung cancer. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test and Log Rank test. NSCLC, non–small-cell lung cancer. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Knockdown of LINC00511 represses NSCLC cell proliferation in vitro. (a,b). CCK8 assay indicate knockdown of LINC00511 represses NSCLC cell proliferation. (c,d). Colony formation assay indicate knockdown of LINC00511 represses NSCLC cell proliferation. (e,f) BrdU staining assay indicate knockdown of LINC00511 represses NSCLC cell proliferation. Bar = 100 μm. (g,h) Representative images and quantification of flow cytometry analysis of A549 and SPC-A-1 cells after transfection. Cell cycle analysis revealed that LINC00511 has influence the proliferation of A549 and SPC-A-1 cells by regulating its cell cycle. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test analysis. NSCLC, non–small-cell lung cancer. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Knockdown of LINC00511 represses NSCLC cell migration and invasion in vitro. (a–d) Transwell migration/invasion assays reveal knockdown of LINC00511 represses NSCLC cell migration and invasion. Bar = 100 μm. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test analysis. NSCLC, non–small-cell lung cancer. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Knockdown of LINC00511 facilitates non–small-cell lung cancer cell apoptosis in vitro. (a,b) Representative images and quantification of flow cytometry analysis of A549 and SPC-A-1 cells after transfection. Cell apoptosis analysis revealed that LINC00511 has influenced the apoptosis of A549 and SPC-A-1 cells. (c,d) Representative images and quantification of Hochest33342 staining of A549 and SPC-A-1 cells after transfection. Bar = 100 μm. (e,f) Quantitative representation of caspase-3 and caspase-7 activity in A549 and SPC-A-1 cells after transfection for forty eight hours. Assays were performed in triplicate. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test analysis. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Knockdown of LINC00511 represses tumor growth in vivo. (a) Representative images tumors isolated from nude mice. (b) Tumor volume in nude mice. (c) Tumor weight in nude mice. Each group contained six mice (n = 5); the data are presented as the mean ± SD; *P < 0.05, compared with the empty vector group. (d) Representative images of H&E, TUNEL, p57, and Ki-67 staining. Bar = 50 μm. Assays were performed in triplicate. *P < 0.05, Means ± SD are shown. Statistical analysis was conducted using student t-test. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 LINC00511 represses p57 expression via directly binding with EZH2 in non–small-cell lung cancer cells. (a) Relative LINC00511 levels in A549 and SPC-A-1 cell cytoplasm or Nucleus were detected by qPCR. GAPDH was used as cytoplasm control and U1 was used as nuclear control. (b) LINC00511 RNA levels in immunoprecipitates with EZH2 antibodies are determined by qPCR. The expression levels of LINC00511 RNA were presented as fold enrichment relative to IgG. (c) SNRNP70 RNA levels in immunoprecipitates with U1 antibodies were used as positive control. (d) EZH2 protein level in immunoprecipitates with LINC00511 RNA is determined by western blot. HuR protein immunoprecipitates with AR RNA was used as positive control. (e) The level of p57 mRNA is determined by qPCR when knockdown of LINC00511 in A549 and SPC-A-1 cells. (f) The level of p57 protein is determined by western-blot when knockdown of LINC00511 in A549 and SPC-A-1 cells. Assays were performed in triplicate. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 LINC00511 recruits EZH2 to p57 promoter and represses their transcription. (a) The EZH2 expression levels were detected by qPCR when knockdown of EZH2 in A549 and SPC-A-1 cells. (b) The p57 expression levels were detected by qPCR when knockdown of EZH2 in A549 and SPC-A-1 cells. (c) ChIP–qPCR analysis of EZH2 occupancy and H3K27me3 binding in the p57 promoter in A549 and SPC-A-1 cells, and IgG as a negative control. (d) ChIP–qPCR analysis of EZH2 occupancy in the MYT-1 promoter in A549 and SPC-A-1 cells, which was used as positive control. (e) ChIP–qPCR analysis of and EZH2 occupancy H3K27me3 binding in the p57 promoter after knockdown of LINC00511. Assays were performed in triplicate. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 8 Silencing of p57 is partly involved in the oncogenic function of LINC00511. A549 and SPC-A-1 cells were transfected with si-NC, si-LINC00511, or cotransfected with si-LINC00511 and si-p57. (a) Relative p57 mRNA expression was tested by qRT-PCR. (b,c) Colony-forming anf BrdU staining assays were performed to determine the cell viability. (d,e) Transwell migration/invasion assays were performed to determine the cell migration and invasion. (f) Quantification of flow cytometry analysis of A549 and SPC-A-1 cells after transfection. Assays were performed in triplicate. *P < 0.05, Means ± SD was shown. Statistical analysis was conducted using student t-test. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 9 Prognostic significance of p57 in lung cancer. (a–c) The effect of p57 mRNA expression level on the overall survival (OS), progression-free survival (FP), and post progression survival (PPS) in lung cancer patients was analyzed and the Kaplan-Meier plots were generated by Kaplan-Meier Plotter (http://www.kmplot.com). (d–f) The effect of p57 mRNA expression level on the overall survival (OS), progression-free survival (FP), and post progression survival (PPS) in lung adenocarcinoma patients was analyzed and the Kaplan-Meier plots were generated by Kaplan-Meier Plotter (http://www.kmplot.com). (g–i) The effect of p57 mRNA expression level on the overall survival (OS), progression-free survival (FP), and post progression survival (PPS) in lung squamous cell carcinoma patients was analyzed and the Kaplan-Meier plots were generated by Kaplan-Meier Plotter (http://www.kmplot.com). Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 10 Hypothesis of the mechanism of LINC00511 on non–small-cell lung cancer. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.94) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions